A novel dominant-negative PD-1 armored anti-CD19 CAR T cell is safe and effective against refractory/relapsed B cell lymphoma

• DOI: 10.1016/j.tranon.2021.101085
• Publication Date: 2021-04-02T06:46:36Z
• Authors: Xiaoqian Liu; Yuanfeng Zhang; Kaimin Li; Yinghui Liu; Junqing Xu; Junjie Ma; Licai An; Hui Wang; Xiaoxia Chu
• Keywords: Cytokine Release Syndrome; Follicular lymphoma; Refractory (planetary science)

Refractory/relapsed B cell lymphoma patients who received the available anti-CD19 chimeric antigen receptor (CAR) T cells may still experience a short duration of remission. Here in this study, we evaluated safety and efficacy novel dominant-negative programmed death-1 (PD-1) armored CAR cells. A total 9 (including 4 diffuse large lymphomas, DLBCL, 2 transformed follicular TFL, 3 FL) infusion at dose more than 1 × 106/kg. Grade ≥ cytokine release syndrome (CRS) neurotoxicity were observed 11.1% (n = 1/9) patients, respectively. The overall response rate (ORR) was 77.8% 7/9) complete (CR) 55.6% 5/9). Two have ongoing CR (all 20+ months). expanded after continued to be detectable 12+ months with CR. This CD19-CAR safe effective durable remissions refractory/relapsed lymphoma.